Study Participants
PAD, cancer, stroke, peripheral artery disease, diabetes
MYOCARDIAL INFARCTION, PERIPHERAL ARTERY DISEASE, STROKE, DISEASE, CANCER, PAD, CHRONIC KIDNEY DISEASE, HEART FAILURE, CEREBROVASCULAR DISEASE, DIABETES
At randomization, the mean age across the 21 820 participants contributing to the main analyses was 67 years, 85.7% were men, 62.6% reported history of MI alone, 11.1% cerebrovascular disease alone, 5.7% peripheral artery disease alone; and the remaining participants reported prior disease histories in 2 or more of these categories or none of these conditions (Table Baseline Characteristics of the 21 820 REVEAL Participants Randomized in Europe and North AmericaCEV indicates cerebrovascular disease; MI, myocardial infarction; PAD, peripheral artery disease; and REVEAL, Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification.The estimated glomerular filtration rate was calculated with the use of the Chronic Kidney Disease Epidemiology Collaboration equation. The missing data were imputed with mean values by sex, smoking status, and trial arm before further analyses.During the 4 years of study follow‐up, 989 out of 21 820 participants (4.5%) experienced an MI, 735 (3.4%) had an urgent CRV, 1047 (4.8%) had a nonurgent CRV, 549 (2.5%) had a nonhemorrhagic stroke, 647 (3.0%) were hospitalized for heart failure, 901 (4.1%) had a noncoronary revascularization, 1618 (7.4%) had an incident cancer, 840 (3.8%) developed incident diabetes, 708 (3.2%) died from a vascular cause, and 960 (4.4%) died from a nonvascular cause.